The simple answer is: not easy. Like all people, doctors get used to the products they use and need a compelling reason to change. Especially when it's something as specialised and delicate as a burr hole in the skull. This is in a different league from medication, where the key ingredients in a new product might be similar to existing meds. So we're up against habit and familiarity, two things that are difficult to shift.
On our side is the fact that there are compelling reasons to change to Osteopore products. I base that on the 20,000 successful operations completed using OSX products. From memory (reading the prospectus) not one patient has experienced complications as is often the case with implants and regular bone-regeneration techniques. There's a ton of verifiable data to back this up, as you'd expect with a company making sensitive medical products. Additionally, OSX has been granted approval to sell in the USA, Europe, China (and other Asian countries I can't recall now) and Australia. This in itself is a big deal to garner support from surgeons.
OSX is not a start-up, it's simply a newly listed company. The company was founded 20 years ago and put in many years with zero income to develop their products to the point where they are now known to be safe and effective. That's what surgeons are interested in. So, while it will still take time to encourage them to jump ship, the reasons for doing so are compelling. Once a few influencers make the move, others will follow.
- Forums
- ASX - By Stock
- Ann: Activities Update Quarter Ending June 2020 and Appendix 4C
OSX
osteopore limited
Add to My Watchlist
0.00%
!
1.2¢

The simple answer is: not easy. Like all people, doctors get...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.081M |
Open | High | Low | Value | Volume |
1.3¢ | 1.3¢ | 1.2¢ | $13.22K | 1.094M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 446472 | 1.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.3¢ | 557877 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 446472 | 0.012 |
7 | 954411 | 0.011 |
7 | 1050000 | 0.010 |
4 | 317111 | 0.009 |
3 | 275001 | 0.008 |
Price($) | Vol. | No. |
---|---|---|
0.013 | 557877 | 3 |
0.014 | 1120133 | 4 |
0.015 | 194010 | 1 |
0.016 | 759159 | 3 |
0.017 | 160000 | 2 |
Last trade - 15.25pm 18/06/2025 (20 minute delay) ? |
Featured News
OSX (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online